聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 50 分钟 59 秒 前

Cordis Corporation Leads With Strong Podium Presence At VEITH 2014 With First-Ever Presentation Of Three-Year INCRAFT(R) System Data

周三, 11/19/2014 - 13:28
FREMONT, Calif., Nov. 19, 2014 -- (Healthcare Sales & Marketing Network) -- Cordis Corporation announced today the presentation of new data from the most recent clinical studies at the 2014 VEITHsymposium®, showcasing the company's diverse and strong ...
Devices, Interventional
Cordis , Johnson & Johnson, INCRAFT System, AAA, stent graft

AdvanDx Receives FDA 510(k) Clearance for mecA XpressFISH(TM)

周二, 11/18/2014 - 19:20
Unique Phenotypic Targeting Approach Provides Physicians with a Better, Faster Way to Identify MRSA and MSSA mecA XpressFISH Gives Blood Culture Results in Approximately One Hour Versus 48-72 Hours WOBURN, Mass., Nov. 18, 2014 -- (Healthcare Sales & Ma...
Diagnostics, FDA
AdvanDx, mecA XpressFISH, MRSA, MSSA

Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology

周二, 11/18/2014 - 19:04
Scientific Pioneers, Industry Veterans Advance Company toward IND Filing CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR-Cas9 technology for gene editing ...
Biopharmaceuticals, Venture Capital
Intellia Therapeutics, CRISPR-Cas9

Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer

周二, 11/18/2014 - 19:00
EWING, N.J.--(Healthcare Sales & Marketing Network)--Antares Pharma, Inc. (ATRS) today announced the appointment of James E. Fickenscher to the position of Senior Vice President, Chief Financial Officer. Mr. Fickenscher has a diversified corporate backgrou...
Biopharmaceuticals, Personnel
Antares Pharma

First U.S. Procedures Completed With The Symphion(TM) Hysteroscopic Tissue Removal System

周一, 11/17/2014 - 16:38
MARLBOROUGH, Mass., Nov. 17, 2014 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (BSX) announces the completion of the first U.S. procedures performed with the Symphion System, designed for the hysteroscopic removal of interute...
Devices, Product Launch
Boston Scientific, Symphion, hysteroscope, hysteroscopic

Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer

周一, 11/17/2014 - 16:09
DUBLIN, Nov. 17, 2014 -- (Healthcare Sales & Marketing Network) -- Actavis plc (ACT) today announced that it has successfully completed its tender offer to purchase all outstanding shares of Durata Therapeutics, Inc. (DRTX), an innovative pharmaceutical c...
Biopharmaceuticals, Mergers & Acquisitions
Actavis, Durata Therapeutics, DALVANCE, antibiotic

Bristol-Myers Squibb to Construct a New Large-Scale Biologics Manufacturing Facility in Cruiserath, Ireland

周五, 11/14/2014 - 12:58
State-of-the-art facility will produce multiple therapies for the company’s growing biologics portfolio Significant investment builds on 50 years of company’s manufacturing history in Ireland 350 to 400 manufacturing jobs and about 1,000 construction...
Biopharmaceuticals
Bristol-Myers Squibb

Integra LifeSciences Announces FDA Clearance and Controlled Market Release of Expandable Interbody System for Spinal Surgery

周四, 11/13/2014 - 13:22
PLAINSBORO, N.J., Nov. 13, 2014 -- (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holdings Corporation (IART) today announced the controlled market release of the Integra(R) Expandable Interbody System, in the United States. The system, whi...
Devices, Orthopaedic, Neurosurgery, FDA
Integra LifeSciences, Expandable Interbody System, spine surgery

Monteris Medical Announces $30 Million Equity Financing

周四, 11/13/2014 - 13:16
PLYMOUTH, Minn., Nov. 13, 2014 -- (Healthcare Sales & Marketing Network) -- Monteris Medical Corporation (Monteris), a pioneer developer of minimally invasive laser systems for the ablation of pathologic brain lesions such as primary and metastatic tumors...
Devices, Neurosurgery, Venture Capital
Monteris Medical, NeuroBlate

Nuvo Research(R) reacquires Pennsaid(R) 2% rights to South America, Central America, South Africa and Israel

周四, 11/13/2014 - 13:11
MISSISSAUGA, ON, Nov. 13, 2014 -- (Healthcare Sales & Marketing Network) - Nuvo Research Inc. (NRI.TO), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it has reacquired Pennsaid 2% mark...
Biopharmaceuticals, Distribution
Nuvo Research, Pennsaid 2%, diclofenac

Blueprint Medicines Secures $50 Million in Series C Financing

周三, 11/12/2014 - 13:45
Proceeds to support continued advancement of highly selective kinase inhibitors to genomically defined cancers, including first-in-class FGFR4 and KIT Exon 17 inhibitors Investor syndicate includes leading public healthcare funds CAMBRIDGE, Mass., No...
Biopharmaceuticals, Oncology, Venture Capital
Blueprint Medicines

Par Pharmaceutical Announces First FDA Approval of Vasostrict(TM) (vasopressin injection, USP)

周三, 11/12/2014 - 13:40
CHESTNUT RIDGE, N.Y., Nov. 12, 2014 -- (Healthcare Sales & Marketing Network) -- Par Pharmaceutical Companies, Inc. today announced that it has received approval for its New Drug Application (NDA) for Vasostrict™ (vasopressin injection, USP) 20 units/mL f...
Biopharmaceuticals, FDA
Par Pharmaceutical, Vasostrict, vasopressin

Beverly Huss Joins Surefire Medical Board of Directors

周三, 11/12/2014 - 13:34
WESTMINSTER, Colo., Nov. 12, 2014 -- (Healthcare Sales & Marketing Network) -- The Board of Directors of Surefire Medical, Inc. today announced the appointment of Beverly Huss as a director of the company. Surefire Medical's novel infusion systems are de...
Devices, Interventional, Oncology, Drug Delivery, Personnel
Surefire Medical, embolization

Globus Medical Announces ALTERA(TM) Minimally Invasive Articulating Expandable Spacer

周三, 11/12/2014 - 13:29
Featured at NASS Booth #1119 AUDUBON, Pa.--(Healthcare Sales & Marketing Network)--Globus Medical, Inc. (GMED), a leading musculoskeletal implant manufacturer, and the worldwide leader in expandable interbody technology, today announced the launch of AL...
Devices, Orthopaedic, Neurosurgery, Product Launch
Globus Medical, ALTERA , interbody fusion, spine surgery

BioCardia(R), Inc. Announces FDA Acceptance of Phase III Clinical Trial Protocol Studying Bone Marrow-Derived Cell Therapy for Heart Failure Patients

周二, 11/11/2014 - 14:25
Company’s CardiAMP™ Therapy is First Cell Therapy for Heart Failure to be regulated by FDA PMA Pathway and First Cell Therapy/Companion Diagnostic to be Studied Together in a Phase III U.S. Trial SAN CARLOS, Calif.--(Healthcare Sales & Marketing Network...
Regenerative Medicine, Cardiology, FDA
BioCardia, CardiAMP

Titan Pharmaceuticals Appoints Two New Board Members

周二, 11/11/2014 - 14:16
SOUTH SAN FRANCISCO, CA--(Healthcare Sales & Marketing Network) - Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has appointed life sciences industry veterans Joseph A. Akers and James McNab Jr. to its board of directors. Mr. Akers, a fo...
Biopharmaceuticals, Personnel
Titan Pharmaceuticals

St. Mary’s Health Care System Expands Cardiac Imaging with Toshiba MR

周二, 11/11/2014 - 14:04
Vantage Titan 1.5T MR Delivers More Efficient Cardiac Exams TUSTIN, Calif.--(Healthcare Sales & Marketing Network)--To build leadership in the region for cardiac care, St. Mary’s Health Care System installed two Vantage Titan™ 1.5T MR systems from Toshi...
Devices, Radiology
Toshiba America Medical Systems, Vantage Titan, MR, imaging

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong